Literature DB >> 6832664

The arthrogrypotic foot plan of management and results of treatment.

S Zimbler, C L Craig.   

Abstract

Fifty-one arthrogrypotic feet have been treated and followed by the Pediatric Orthopaedic Unit, Tufts New England Medical Center, (1970-1980). Forty of the 51 feet presented as equinovarus with the residual divided among metatarsus adductus, vertical tali, and calcaneovalgus. Equinovarus deformities are the most resistant in all cases. Corrective casts are applied for at least the first 3 months of life. Surgical procedures were then initiated with any evidence of lack of progression of treatment. Varus and equinus were treated by an extensive posterior and medial release. Lateral soft tissue releases in addition to calcaneocuboid fusion or cuboid osteotomy were necessary in 24 of the 70 operations. Recurrence rate has been a problem in the simple type of posterior release including only an Achilles tendon lengthening, and posterior capsulotomy of the ankle and subtalar joint. Talectomy has been carried out in four feet and appears to be one type of reasonable salvage procedure in smaller children with recurrent varus. Treatment is difficult in these patients but a plantigrade foot should be achieved in all cases.

Entities:  

Mesh:

Year:  1983        PMID: 6832664     DOI: 10.1177/107110078300300406

Source DB:  PubMed          Journal:  Foot Ankle        ISSN: 0198-0211


  3 in total

1.  Correction of arthrogrypotic clubfoot with a modified Ponseti technique.

Authors:  Harold J P van Bosse; Salih Marangoz; Wallace B Lehman; Debra A Sala
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

2.  Results of the Ponseti method in patients with clubfoot associated with arthrogryposis.

Authors:  Jose A Morcuende; Matthew B Dobbs; Steven L Frick
Journal:  Iowa Orthop J       Date:  2008

3.  Challenging clubfeet: the arthrogrypotic clubfoot and the complex clubfoot.

Authors:  H J P van Bosse
Journal:  J Child Orthop       Date:  2019-06-01       Impact factor: 1.548

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.